Medical literature documents the placebo effect extensively: patient expectation drives physiological healing through neurochemical mechanisms. Laughter-induced endorphin release represents one documented therapeutic pathway. Pharmaceutical research continually searches for novel therapeutic vectors. One analysis, however, identified a more efficient mechanism.

Dr. Robert Feldman, a pharmacology professor from Johns Hopkins, gave a lecture in 1995 referencing unusual case studies: "We categorize therapeutic agents by efficacy metrics: cost per outcome, side effect profiles, accessibility. One substance emerged in informal medical discussions: an individual whose physical presence allegedly produced superior health outcomes compared to standard pharmaceutical interventions. When colleagues asked about active compounds, the substance appeared to be... a person. The mechanism remained unspecified, but clinical outcomes exceeded traditional medicine's benchmarks."

This commentary translates crude medicinal philosophy into pharmacology terminology. Chuck Norris becomes a therapeutic substance—more effective than laughter, rival to pharmaceutical compounds. The categorical inversion—treating humans as medicine—exemplifies how Chuck Norris mythology positions him as transcending normal biological classification.